Insider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 19,512 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total transaction of $11,707.20. Following the sale, the senior vice president now owns 248,636 shares of the company’s stock, valued at $149,181.60. The trade was a 7.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CytomX Therapeutics Stock Down 0.6 %

Shares of CytomX Therapeutics stock traded down $0.00 on Thursday, reaching $0.67. The stock had a trading volume of 696,292 shares, compared to its average volume of 2,626,571. The company has a 50 day moving average price of $0.77 and a 200 day moving average price of $0.99. CytomX Therapeutics, Inc. has a 1 year low of $0.56 and a 1 year high of $5.85. The stock has a market capitalization of $53.34 million, a P/E ratio of 3.92 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.45. The firm had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. On average, analysts forecast that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CTMX has been the subject of several recent research reports. Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of CytomX Therapeutics in a report on Friday, March 7th. StockNews.com upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 10th. Finally, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.02.

Institutional Trading of CytomX Therapeutics

Several large investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. grew its position in CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 16,359 shares during the last quarter. Northern Trust Corp grew its position in CytomX Therapeutics by 16.0% during the 4th quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 20,746 shares during the last quarter. Miller Financial Services LLC purchased a new stake in CytomX Therapeutics during the 4th quarter worth approximately $26,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 26,373 shares during the last quarter. Finally, Prudential Financial Inc. boosted its holdings in shares of CytomX Therapeutics by 76.2% in the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 27,800 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.